Clinical Safety · Updated May 2026

Emergency Response Protocols

ACLS-equipped facility, 24/7 physician coverage, written hospital transfer agreement, quarterly scenario drills. The exact response protocols our team executes for cardiac, neurological, and psychiatric emergencies during ibogaine treatment.

🚨 ACLS-current medical staff📡 Continuous telemetry 72-96 h🏥 Written hospital transfer agreement

Quick Answer

What emergency protocols are in place during ibogaine treatment at MindScape?

MindScape Retreat maintains continuous cardiac telemetry from pre-medication through 72–96 hours post-dose, an ACLS-equipped crash cart with defibrillator within 30 seconds of every patient bed, ACLS-current physicians and nurses on-site, written transfer agreements with a tertiary cardiology hospital in Cozumel, and quarterly timed scenario drills covering torsades, bradycardia, anaphylaxis, prolonged psychoactive states, and psychiatric crisis.

Medically reviewed by Dr. Arellano, M.D. — Last reviewed May 2026

The Safety Logic

Why a written, drilled emergency protocol is the difference between credible care and aspirational marketing.

The honest framing. Ibogaine is a powerful pharmacological intervention with real cardiac, neurological, and psychiatric risk. Most credible clinics screen carefully and monitor continuously, and the published outcome data reflect that approach. But the difference between a clinic that has these protocols documented, drilled, and executable — and one that has them as a slide deck — only shows up in the rare moments when something actually goes wrong.

What makes a protocol real. A real protocol has (1) a defined trigger that is detectable in real time by available monitoring, (2) immediate response steps the team has practised, (3) a clear escalation threshold, (4) a documented hospital transfer agreement with the receiving facility, and (5) an after-action review process. We have all five for every scenario on this page. Quarterly drills test them under time pressure.

What this page is — and is not. This is the public summary of our internal clinical SOPs. It is not a substitute for the full SOP binder our staff work from, which includes drug doses, vital-sign thresholds, paging trees, and patient-specific contingencies. We publish this summary because patients and referring physicians have a right to see how we handle worst-case scenarios — not as marketing copy, but as evidence the readiness exists.

Documented Response Protocols

QTc prolongation > 500 ms

Trigger: Continuous telemetry detects QTc crossing 500 ms (or >60 ms above baseline)

Immediate Response

Hold any further ibogaine administration immediately
Verify magnesium and potassium serum levels; replete IV magnesium sulfate (2 g) if Mg < 2.0 mg/dL
Repeat 12-lead EKG at 30, 60, and 120 minutes
Place defibrillator pads on patient as a precaution
Continuous physician bedside presence

Escalation Path

If QTc remains > 500 ms after IV magnesium and electrolyte correction, or if T-wave morphology becomes unstable, transfer to our partner hospital cardiology unit under code-status protocol.

Torsades de pointes (polymorphic VT)

Trigger: Telemetry detects polymorphic ventricular tachycardia

Immediate Response

Initiate ACLS protocol — IV magnesium sulfate 2 g push
If sustained VT or hemodynamic instability: defibrillation per ACLS
Hold all QTc-prolonging interventions
Establish IV access if not already present
Activate hospital transfer agreement; notify partner cardiology unit

Escalation Path

Direct transfer by ACLS-equipped ambulance to partner hospital. Patient does not return to retreat without cardiology clearance.

Vasovagal syncope / bradycardia

Trigger: Heart rate < 45 bpm with symptomatic hypotension, or syncopal episode

Immediate Response

Place patient supine, legs elevated
IV fluid bolus (500 ml normal saline)
Atropine 0.5 mg IV if bradycardia persists with hemodynamic compromise
Continuous telemetry through resolution
12-lead EKG once stable

Escalation Path

If bradycardia is refractory or recurrent, transfer to partner hospital for cardiology evaluation and possible pacemaker assessment.

Severe ataxia preventing safe ambulation

Trigger: Patient unable to stand or transfer safely; risk of falls

Immediate Response

Transfer patient to monitored bed with side rails
Continuous physician observation through peak ataxia (typically 4-8 hours post-dose)
Bedside urinal / bedpan to eliminate fall risk during bathroom transfers
Two-person assist for any required movement
IV hydration to support clearance

Escalation Path

Ataxia is expected during the acute ibogaine window; this protocol manages it without escalation in the vast majority of cases. Persistent ataxia beyond 24 hours triggers neurological consultation.

Prolonged psychoactive state (> 36 h)

Trigger: Visionary state or altered consciousness persists beyond 36 hours post-dose

Immediate Response

Verify ibogaine and noribogaine plasma levels (send-out lab)
Rule out hypoglycemia, electrolyte abnormality, hepatic encephalopathy
Continuous physician bedside with calming, oriented presence
Avoid benzodiazepines unless indicated for seizure activity
IV hydration and electrolyte support

Escalation Path

If altered mental status persists or worsens beyond 48 hours, transfer to partner hospital for neurology consultation. Most cases resolve with hydration and time.

Psychiatric crisis during integration

Trigger: Patient expresses active suicidal ideation with plan, severe dissociation, or psychotic symptoms post-dose

Immediate Response

Continuous one-on-one staff presence
Remove access to means (medications, sharp objects)
Psychiatrist consultation within 4 hours (24/7 on-call)
Involve patient's pre-arranged contact person if appropriate
Do not initiate involuntary medication; orientation, validation, and safety are first-line

Escalation Path

If risk remains high after 24 hours of structured support, transfer to partner psychiatric facility under safe-transport protocol. Coordinate continuity of care with patient's home psychiatrist.

Anaphylaxis or severe allergic reaction

Trigger: Hives, angioedema, bronchospasm, or hemodynamic compromise within minutes to hours of any administered medication

Immediate Response

Epinephrine 0.3 mg IM (auto-injector or syringe) immediately
Position patient supine, elevate legs
Oxygen via non-rebreather mask
IV access; IV fluid bolus
Repeat epinephrine every 5-15 minutes if symptoms persist
Adjuncts: H1 antihistamine, H2 antihistamine, methylprednisolone

Escalation Path

Hospital transfer for observation regardless of initial response — biphasic anaphylaxis can occur 4-12 hours later.

What's Onsite

The clinical readiness inventory.

Cardiac monitoring and resuscitation. 12-lead EKG and continuous telemetry at every bed; ACLS cart with biphasic defibrillator (with pacing); full ACLS pharmacology (epinephrine, atropine, amiodarone, magnesium sulfate, lidocaine, calcium, sodium bicarbonate, vasopressin); oxygen, bag-valve-mask, and advanced airway equipment.

Medical staff coverage. Board-certified physicians on-call 24/7; ACLS-current nursing through the entire dosing and clearance window; one-on-one staffing during peak ataxia and visionary phases; psychiatrist on-call for integration crises.

Pharmacy and IV capability. Full IV fluid panel, electrolyte repletion (magnesium sulfate, potassium chloride), benzodiazepines for seizure management, corticosteroids and antihistamines for allergic reactions, naloxone, glucose for hypoglycemia.

Transport and hospital integration. ACLS-equipped ambulance stationed within 5 minutes; written transfer agreement with tertiary-care hospital in Cozumel providing cardiology, neurology, and psychiatric services; physician coverage en route.

Documentation and reporting. Real-time charting on every patient; written SOPs accessible at every clinical bed; mandatory after-action review within 72 hours of any serious adverse event; submission to relevant adverse-event registries; full transparency to the patient and their referring physician.

Emergency Protocol FAQ

What patients, families, and referring physicians ask about our readiness.

Our facility maintains a fully-equipped advanced cardiac life support (ACLS) cart at all times: defibrillator with pacing capability, full ACLS pharmacology (epinephrine, atropine, amiodarone, magnesium sulfate, lidocaine, calcium chloride, sodium bicarbonate), oxygen and bag-valve-mask, advanced airway equipment, and IV supplies. Our medical staff are ACLS-current. Continuous telemetry runs from pre-medication through 72-96 hours post-dose. The defibrillator is positioned within 30 seconds of every patient bed.

We maintain a written transfer agreement with a tertiary-care hospital in Cozumel with cardiology, neurology, and psychiatric services. Transfer is by ACLS-equipped ambulance staffed by our medical team, with continuous telemetry and physician coverage en route. We have run drilled transfer scenarios, including timed runs, to verify the protocol works in practice — not only on paper.

Infrequently. Most escalations in our experience are precautionary observations after vasovagal episodes that resolve quickly, or for biphasic anaphylaxis monitoring after a controlled medication reaction. Cardiac transfers for sustained QTc abnormality or torsades remain rare under our screening and monitoring protocol. We track transfer frequency internally as a quality signal and publish aggregate outcome data on our /outcomes page.

Magnesium is the first-line treatment for QTc prolongation and torsades de pointes per AHA / ACLS guidelines. It works regardless of the underlying serum magnesium level and stabilises cardiac repolarisation independent of the trigger. Our protocol pre-loads magnesium before flood-dose administration (per the Stanford 2024 paradigm), maintains serum Mg > 2.0 mg/dL throughout the noribogaine clearance window, and has an IV magnesium dose drawn and ready at every bedside before dosing begins.

Yes. Our medical director is a board-certified psychiatrist and we maintain 24/7 psychiatry on-call coverage. Most acute psychiatric distress during integration is, in our clinical experience and consistent with current integration practice, managed first with structured one-on-one staff presence, orientation, validation, and time rather than pharmacological sedation. We have written protocols for acute suicidal ideation, severe dissociation, and emergent psychotic symptoms. Our partner psychiatric facility provides higher-acuity care if a patient cannot be safely managed onsite.

Yes. Our medical team runs quarterly scenario drills covering each protocol category — cardiac arrest, torsades, anaphylaxis, prolonged psychoactive state, psychiatric crisis, hospital transfer. Drills are timed and debriefed. New staff complete a structured onboarding programme that includes scenario participation before independently covering shifts. ACLS recertification is mandatory and tracked. The protocols on this page are the operational standards our team trains against; drill records are maintained internally and are available to referring physicians on request.

Yes — populations with elevated baseline risk receive enhanced monitoring. Veterans with combat-related TBI receive additional neurological monitoring per the Stanford 2024 paradigm. Patients with prior cardiac history receive cardiology consultation pre-dose and tighter QTc monitoring thresholds. Patients with severe trauma history have a dedicated psychotherapist on-call during integration. Patients flagged as CYP2D6 poor metabolisers or on CYP2D6 inhibitors receive extended telemetry through the longer noribogaine clearance window.

We document, debrief, and report. Every serious adverse event triggers an internal root-cause analysis within 72 hours, a written report to the patient and their referring physician, and (where applicable) submission to the relevant adverse-event registries. Lessons learned feed back into protocol revision. Our medical director reviews every adverse event personally. We do not delete records, suppress findings, or contest legitimate complaints — transparency is part of how the field gets safer.

Medically reviewed by Dr. Arellano, M.D.

Clinical Director, MindScape Retreat · Board-certified physician specializing in ibogaine-assisted detoxification with over 900 patients treated.

Last reviewed: May 2026 · See full medical team

Pre-Treatment Safety Review

The protocol you do not need is the one we drill the hardest.

A free, confidential safety and readiness consultation with our admissions physician — usually within 24 hours.

Book Safety Consultation

100% Confidential · No Obligation